These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22175076)

  • 21. [Comments on the editorial "The health sector and the perpetual murkiness in the relations between the medical profession and the drug industry" ].
    Oteo Ochoa LA
    Rev Calid Asist; 2009 Aug; 24(4):178-81. PubMed ID: 19647681
    [No Abstract]   [Full Text] [Related]  

  • 22. India sets its sights on global health care market.
    Jayaraman KS
    Nat Med; 2003 Apr; 9(4):377. PubMed ID: 12669044
    [No Abstract]   [Full Text] [Related]  

  • 23. Shaping the future of safer innovative drugs in Europe.
    Mestres J; Bryant SD; Zamora I; Gasteiger J
    Nat Biotechnol; 2011 Sep; 29(9):789-90. PubMed ID: 21904315
    [No Abstract]   [Full Text] [Related]  

  • 24. Lowering the High Cost of Cancer Drugs--II.
    Messori A; Fadda V; Trippoli S
    Mayo Clin Proc; 2016 Mar; 91(3):397-9. PubMed ID: 26944244
    [No Abstract]   [Full Text] [Related]  

  • 25. Market watch: upcoming market catalysts in Q4 2012.
    Tucker J
    Nat Rev Drug Discov; 2012 Oct; 11(10):740. PubMed ID: 23023671
    [No Abstract]   [Full Text] [Related]  

  • 26. The perverse consequences of a proposed global tax on research.
    MacDonald C; Walton N
    Am J Bioeth; 2010 Jun; 10(6):46-7. PubMed ID: 20526972
    [No Abstract]   [Full Text] [Related]  

  • 27. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What is the fair price of innovative therapy?].
    Fischer A; Dewatripont M; Goldman M
    Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How the UK is attempting to boost its life sciences industry and speed up the adoption of innovation at the bedside.
    Wilkinson E
    Eur Heart J; 2012 Jun; 33(11):1295-6. PubMed ID: 22838022
    [No Abstract]   [Full Text] [Related]  

  • 30. [Laqueur and organon: the university laboratory and the pharmaceutical industry in the Netherlands].
    Oudshoorn N
    Tijdschr Geschied Geneeskd Natuurwet Wiskd Tech; 1999; 22(1):12-22. PubMed ID: 20677414
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel schemes skirt NICE barrier.
    Elvidge S
    Nat Biotechnol; 2011 Aug; 29(8):677. PubMed ID: 21822231
    [No Abstract]   [Full Text] [Related]  

  • 32. Dollars & sense of the health care industry.
    Tremayne WH
    N J Med; 1998 May; 95(5):71-3. PubMed ID: 16013161
    [No Abstract]   [Full Text] [Related]  

  • 33. Marc Kirschner. Interview by Asher Mullard.
    Kirschner M
    Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
    [No Abstract]   [Full Text] [Related]  

  • 34. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
    Bender S; Flicker L; Rhodes R
    Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
    [No Abstract]   [Full Text] [Related]  

  • 35. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 36. Busy period for Bristol-Myers Squibb.
    Payne T
    Future Med Chem; 2012 Sep; 4(13):1659. PubMed ID: 22924503
    [No Abstract]   [Full Text] [Related]  

  • 37. An innovative approach to the care of patients on phase I and phase II clinical trials: the role of the experimental therapeutics nurse.
    Carlson C; Reilly M; Hitchens A
    J Pediatr Oncol Nurs; 2005; 22(6):353-64. PubMed ID: 16216897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 39. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conflicts of interest with the health industry.
    Dubois MY
    Pain Med; 2006; 7(5):463-5. PubMed ID: 17014609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.